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ABSTRACT 
 
 
Background: Aberrant phenotype has been reported in acute leukemias with 
varying frequency in various studies . Its prognostic importance still remains 
controversial. In acute myeloid leukemias, aberrant phenotype, as high as 88 %, 
has been reported. In the current study, 35 samples of  newly diagnosed acute 
myeloid leukemia were analyzed to evaluate the frequency of aberrant phenotypes. 
Aberrant phenotypes were also correlated with known prognostic factors such as 
gender, age, WBC count, platelet count and  blast percentage. 
Materials and Methods: Whole blood or bone marrow aspirate collected in 
EDTA were processed by standard method and subjected to flowcytometric  
immunophenotyping for marker CD3,  CD7,  CD10  ,CD13,  CD14 ,CD15, CD19 
CD33, CD34 and CD117. 
Results: Aberrant lymphoid markers were seen in 17( 49%)cases . 5 cases had 
lymphoid associated antigen expression alone  which is 14 % of cases. 3 cases had 
asynchronous antigen expression alone which is 8%  of cases.  9 cases had both 
asynchronous antigen expression and lymphoid associated antigen expression 
which is 27 % of cases . In total lymphoid associated antigen expression is seen in 
41 % of cases and asynchronous antigen expression in 35 % of cases. CD3 , CD19 
( lymphoid associated antigen )   and CD34+ CD15+ (asynchronous aberrant 
phenotype ) were the most common equally expressed aberrant phenotypes, each 7  
cases. CD 7 was seen in 4 cases , 28.6% of  Ly + AML  aberrant phenotypic cases. 
CD 3 was  significantly more common in males (P=0.021) but in general there 
were no statistically significant association between poor prognostic factors and 
aberrant phenotypic AML. 
Conclusion: There is a  frequent occurrence of aberrant phenotype in acute 
myeloid leukemia in India like in other majority of  studies  . CD19  and CD3 were 
the most commonly expressed lymphoid associated antigen. Lymphoid associated 
expression were slightly more common than asynchronous antigen expression. 
Most common asynchronous aberrant phenotype was CD34+CD15+. Aberrant 
phenotypic expression were not associated with poor risk factors in acute myeloid 
leukemia except for common expression of CD3 in males. 
 
Key words:  Aberrant phenotype; Flow cytometry; AML ;Prognosis ; Lymphoid 
associated antigen ; asynchronous antigen. 
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INTRODUCTION 
 
Acute myeloid leukemia (AML) is a heterogeneous disease, presenting with a high 
diversity of phenotypes . Immunophenotype in acute myeloid leukemia (AML) 
had remained elusive. In recent years, along with the wide application of AML 
immunophenotype testing, immunophenotype itself and its relationship with 
genetics and morphology became better understood . 
 
The latest WHO 2008 classification of acute leukemia uses morphology, 
immunophenotype, genetics and clinical features to define clinically significant 
disease entities . Distinction between acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) is extremely important and flowcytometry (FCM) 
is very instrumental in this. Malignant blasts often have an abnormal phenotype 
that allows distinction from normal immature cells .  
 
Aberrant phenotype is a well known phenomenon in acute myeloid leukemia.  
Currently, the aberrant phenotypes are classified into different types: co-expression 
of lymphoid-associated antigens or lineage infidelity; asynchronous antigen 
expression, in which early antigens are coexpressed with more mature ones; or  
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antigen overexpression and existence of abnormal light scatter patterns.  
 
Aberrant antigen expression is reported to have variable frequency . The most 
frequent lymphoid antigens in AML that have been reported include, CD7 (T-cell 
marker) and CD19 (B-cell marker). In AML, characteristic antigens have been 
related to particular morphological FAB subtypes and associated with the presence 
of recurrent genetic abnormalities such as AML-M2 with t(8;21) that shows 
aberrant expression of lymphoid markers include CD19 and CD56 another one is 
co-expression of CD2 in M4E with inv(16) or t(16; 16), although not specific for 
this type of AML and M5 with t(9;11) is reported to have high expression CD56.  
 
One of the newly emerging importance of immunophenotypical aberrancies using 
FCM is the detection and quantification of minimal residual disease (MRD) for 
providing prognostic information, and make use of such aberrancies in routine 
management of patients to guide therapy  . Prognostic value of aberrant phenotype 
and its association with adverse clinical, hematological, and other biological 
prognostic factors in acute myeloid leukemia is still controversial. In some studies, 
the aberrant phenotypes were found to be of prognostic significance while other 
studies report no difference between aberrant and normal phenotype. In the 
literature, Ly + AML phenotypes have been shown to be associated with both poor  
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as well as favorable prognosis .However, no difference has also been reported for 
the clinical features and outcome between normal and aberrant phenotype of 
childhood AML . Based on coexpression and correlation of lineage-associated 
antigens, multiparameter high-resolution flow cytometry has been developed to 
precisely identify lineage characteristics of leukemia. Immunophenotyping 
improves both accuracy and reproducibility of acute leukemia classification and is 
considered particularly useful for identifying poorly differentiated subtypes of 
acute leukemia, acute myeloid leukemia (AML) with lymphoid marker expression 
and acute lymphatic leukemia (ALL) with myeloidmarker expression. 
Immunological studies of leukemic blasts have become critical also for identifying 
biphenotypic and bilineal acute leukemias.  
 
At present, while the prognostic value of individual antigen expressions is still 
controversial, it is important in the immunologic detection of minimal residual 
disease, especially in AML, as it seems to be important in monitoring the acute 
leukemia patients in remission There is much to be discovered about the  
characteristics and significance of co-expression of two or more aberrant lineage 
leukemia markers. 
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In the current study, 35 samples of  newly diagnosed acute myeloid leukemia were 
analyzed to evaluate the frequency of aberrant phenotypes. Aberrant phenotypes 
were also correlated with known prognostic factors such as gender, age, WBC 
count, platelet count and  blast percentage. 
. 
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AIMS AND OBJECTIVES 
 To study about the aberrant phenotypes in acute myeloid leukemia in India. 
 To study the correlation among the aberrant phenotypes and poor prognostic 
factors in acute myeloid leukemia. 
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REVIEW  OF  LITERATURE 
DEFINITION 
Acute myelogenous leukemia is a clonal, malignant disease of hematopoietic 
tissue. 
There is                                                                                                                           
(1) accumulation of  myeloblasts  mainly in the bone  marrow and                                    
(2) impairment of production of normal hematopoietic cells. 
EPIDEMIOLOGY 
Acute myeloid leukemia is common in neonates but less common in children and 
adolescents. Males are slightly more commonly involved than females. The 
mortality rate from  acute myeloid leukemia is approximately 0.5 / lakh patients 
younger than 10 yrs. Mortality rate increases after that and reaches up to  20/lakh  
patients in their nineties.  
POPULATION INCIDENCE 
ASIAN LOWER 
EASTERN  EUROPEAN HIGHER 
SPANISH(APL) HIGHER 
DEVELOPED NATIONS HIGHER 
INDUSTRIALIZED CITIES HIGHER 
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AML accounts for 80 to 90% of cases of acute leukemia in adults and in children 
about 15 to 20%. With increasing age the incidence increases , with a median of 67 
years. For people less than 25 yrs. it is less than 1/100,000, but  for octogenarians 
of it is 25/100,000.  
INDIAN SCENARIO 
According to comparison of incidence rates of all PBCR’s(Population Based 
Cancer Registry) under National Cancer Registry Programme (NCRP India),for the 
year 2006-2008, Aziwal district of Mizoram showed highest age adjusted 
incidence rates  of 5.6 per lakh population in males, followed by rest of Mizoram 
state with 3.2/lakh population. In females Imphal west district 2.7 per lakh 
population  registered the highest age adjusted incident rate followed by 
thiruvanantapurum  2.3 per lakh & Ahmedabad 2.1 per lakh . The overall annual 
incidence is 3.7/100,000 persons. 
ETIOLOGY AND PATHOGENESIS: 
CONDITIONS PREDISPOSING TO DEVELOPMENT OF AML: 
Environmental factors: 
• Radiation1 
• Benzene2 
• Alkylating agents 
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• Topoisomerase II inhibitors 
• Tobacco smoke3 
Acquired diseases: 
Clonal myeloid diseases; 
• CML 
• Primary myelofibrosis 
• Essential thrombocythemia 
• Polycythemia vera 
• PNH 
Other hematopoietic disorders: 
• Aplastic anemia 
• Myeloma 
Other disorders: 
•HIV 
•Thyroid disorders 
•Poly endocrine tumours 
Inherited or congenital conditions:  
•Sibiling  with AML  
•Rothmund-Thomson syndrome 
•Bloom syndrome 
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•Diamond-Blackfan syndrome 
•Down syndrome 
•Fanconi syndrome 
•Neurofibromatosis 
•Noonan syndrome 
•Dyskeratosis congenita 
•Ataxia-pancytopenia 
•Familial platelet disaorder 
Molecular Pathogenesis: 
Hematopoietic multipotential cell or lineage restricted progenitor cell are affected 
by series of somatic mutations. The acute myeloid leukemia stem cell is found to 
be CD123 positive ,CD45 dim, CD34 positive , CD38 negative.
4
 Chromosomal 
translocations are the most somatic mutations which results in the fusion gene 
which produces fusion protein.
5 
 Fusion protein halts the regulatory sequence 
controlling the progenitor cells. The cell differentiation , maturation and 
proliferation are affected by dysregulated signals. In APL the fusion protein 
prevents the promyelocyte maturation by  repressing  retinoic acid inducible 
genes.
6,7 
 Hence results in leukemia.  
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AML develpoment as multistage process 
 
 
11 
 
 
Clinical features of acute myeloid leukemia. 
 The AMLs usually present with some combination of granulocytopenia, anemia, 
thrombocytopenia, and the appearance of immature cells (blasts) in blood and 
marrow. The classic presentation of AML in an otherwise healthy patient is most 
often seen in young adults. Older patients can present with atypical aspects such as 
a pre-existing myelodysplastic syndrome or a slow onset of the disease 
(smouldering leukemia). AML in younger patients is a catastrophic illness. The 
entire clinical history is seldom more than a few weeks long and is characterized 
by the sudden appearance of fatigue, fever, bacterial infections of the upper 
respiratory tract, bone pain, and various bleeding manifestations. These are signs 
and symptoms associated with marked anemia, granulocytopenia, and 
thrombocytopenia. 
Clinical features of anemia are present. Characteristically, symptoms can be out of 
proportion to the severity of anemia. Thrombocytopenia results in bleeding 
manifestations. Physical findings in the AML patient include pallor from the 
anemia, skin and mucous membrane bleeding, aphthous ulcers, gingivitis and 
pharyngitis, and, on occasion, sternal tenderness. Minor skin infections can occur . 
Major infections are rare before chemotherapy. Cancer cachyxia and significant 
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weight loss are common. Palpable hepatospleenomegaly occurs in 30 % of the 
patients. Lymphadenopathy is   seen only in the M4 M5 FAB subtypes of acute 
myeloid leukemia.  
Specific Organ System   
Extramedullary infiltration is most common in M4 M5 FAB subtypes of acute 
myeloid leukemia.
8 
Skin involvement may be  
 Leukemia cutis or 
 Myeloid sarcoma or 
 Nonspecific lesions  
There may be involvement of sensory organ like retina ,optic nerve and cochlea.
9 
 The gastrointestinal symptoms are mostly organic. Patient may present to the 
dentist for gingival infiltration resulting in tooth extraction. Diarrhoea due to 
proctitis can occur in
 
M4 and M5 subtypes. 
 Cardiac involvement though frequent but are asymptomatic. Infiltration into 
the pericardium, myocardium, endocardium and into the conduction system 
can occur.
10
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 Kidneys can also be affected . 
 Nervous system involvement is not so common but can occur in monocytic 
type of acute myeloid leukemia.
11
 
  Bone pain and necrosis can occur. 
  Patients with high levels of primitive blasts (greater than 100,000/µL) can 
present with a leukostasis syndrome characterized by ischemia of multiple 
organs and both pulmonary and central nervous system dysfunction (Ball 
disease). This situation is a true hematologic emergency and needs to be 
treated immediately with combination chemotherapy and leukopheresis to 
prevent death. 
Chloroma  
 They may present alone without the involvement of bone or marrow. It may 
be initial manifestation. They are rich in MPO which gives it green colour 
hence named as chloroma. They can be found anywhere in the body. 
Patients with chloroma and translocation involving 8 and 21 chromosome 
have poor prognosis.
11
 
LEUKEMIA CLASSIFICATION 
Initially it was a purely morphologic classification. However, over the years it has 
been bolstered by immunohistochemical and immunologic data, using markers for 
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different stages of myeloid differentiation. Even with this information, the 
overriding principle of leukemia classification continued to be the placement of the 
malignant cell in the normal scheme of hematopoietic cell differentiation. The 
most recent modification of the classification of AML, proposed by a World 
Health Organization conference, goes a step further. It takes into account both 
genetic information and whether AML arises de novo or evolves from a 
myelodysplastic syndrome in the classification . This approach is likely to continue 
to evolve in the future as new information regarding cell biology, therapeutic 
response, and outcome becomes available. Gene-expression profiling using 
microarray technology is expected to have a major impact on leukemia 
classification 
 WHO Classification of AML 
        AML with recurrent genetic abnormalities 
        AML with multilineage dysplasia 
        AML and MDS, therapy-related 
        AML not otherwise categorized 
        AML  of ambiguous lineage  
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FAB classification of acute myeloid leukemias. 
Cell Type FAB Description Incidence 
(%) 
Undifferentiated M1 Blasts with bland characteristics 20 
Myeloblastic M2 Blasts with early granulocytic differentiation 30 
Promyelocytic M3 Clear promyelocytic characteristics 10 
Myelomonocytic M4 A mixture of granulocytic and monocytic 
characteristics 
25 
Monocytic M5 Clear monocytic characteristics 10 
Erythroleukemic M6 Blasts with erythroid characteristics 4 
Megakaryocytic M7 Blasts with megakaryocytic properties 1 
 
 
Diagnosis 
Usually diagnosed by the myeloblasts in the PS . Bone marrow aspiration is 
mandatorily done for the diagnosis. Bone marrow aspirate is subjected to 
 Morphological examination  
 Histochemistry 
 Immunophenotyping  
16 
 
 Molecular markers study 
 Cytogenetic study 
COMPLETE BLOOD COUNT 
The complete blood count (CBC) will demonstrate varying combinations of 
anemia, granulocytopenia, and thrombocytopenia, together with the appearance of 
abnormal immature cells (blasts) in circulation. The total number of blasts will 
vary from a small percentage  of the circulating cells to an overwhelming, uniform 
population of primitive blasts, exceeding 50,000/µL. Loss of other normal cell 
elements also helps make the diagnosis. The malignant event responsible for 
proliferation of the leukemic cell line also blocks normal granulocyte, red blood 
cell, and platelet production. At the same time, small numbers of normal 
lymphocytes will still be present. Presence of lymphocytes but absence of normal 
granulocytes in circulation suggests involvement of the myeloid cell line in the 
leukemic process. Up to 10% of leukemias can present as aleukemic leukemia, that 
is, as pancytopenia with few if any blasts in circulation. In this situation, marrow 
aspirate and biopsy invariably give the diagnosis. In patients who gradually evolve 
to AML as an endpoint of a myeloproliferative disorder, the pattern of the 
cytopenia may be quite variable. In addition, some of these patients will 
demonstrate a macrocytic anemia, marked poikilocytosis with nucleated red blood 
cells on the peripheral film, or both. 
17 
 
MARROW ASPIRATE AND BIOPSY 
A marrow aspirate and biopsy should be obtained in all patients. Sufficient 
material should be collected for routine morphology and histochemical staining, 
immunophenotyping, and chromosomal analysis. This process will require several 
aspirations and may involve several placements of the marrow aspirate needle.A 
marrow biopsy core should be obtained from a separate site at some distance from 
the point of marrow aspiration to guarantee an adequate specimen. The biopsy is 
important to determine overall cellularity, the distribution of the malignant process, 
and any tendency to fibrosis. Rarely, an AML patient will present with a packed or 
even necrotic marrow that defies aspiration. In this case, the biopsy is critical. 
 
Morphology   
The maturation of myeloid cells in the marrow is relatively easily followed based 
on morphologic criteria . Several characteristics of the maturation sequence are 
used in classifying the leukemic cell line. The first of these is the appearance of 
cytoplasmic granules in the maturing granulocytes. The most primitive 
(undifferentiated) myeloblasts have no granules and are difficult to distinguish 
from lymphoblasts. As the cell line matures to the promyelocyte stage, primary 
granules become abundant and partially obscure the nucleus .Some patients with 
promyelocytic leukemia have microgranular morphology. Malignant myeloblasts 
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and promyelocytes can also contain abnormal rod-shaped granules known as Auer 
rods . When present, Auer rods are by far the best criterion for identifying 
leukemic myeloid cells in the granulocytic lineage. As myelocytes mature further, 
they acquire secondary granules that are smaller and more heterogeneous in their 
staining properties. When cells follow the monocytic differentiation pathway, 
cytoplasmic granules are never as prominent as those in granulocytes. They are 
smaller, scantier, and remain pink to purple. The categorization of leukemias as 
myelomonocytic reflects the difficulty in distinguishing between immature cells of 
the granulocyte and monocyte lineages. Finally, acute eosinophilic and basophilic 
(mast cell) leukemias are readily identified from the distinctive granules within the 
cytoplasm. 
These stains are used in conjunction with conventional morphology in the FAB 
classification system.The second most important morphologic criterion in the 
detection of a myeloid leukemia is the morphology of the nucleus. The chromatin 
of immature cells such as myeloblasts is characterized by a very fine, lacy pattern. 
As the cell matures, the chromatin becomes progressively more coarse or clumped. 
Moreover, the nature of the clumping is different in granulocytes, lymphocytes, 
and monocytes. The nucleus in the granulocyte lineage first folds at the 
metamyelocyte stage and then becomes segmented, whereas the nucleus of the 
developing monocyte remains indented or horseshoe shaped. Nucleoli are another 
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sign of immaturity. They are invariably present in immature blasts and are lost 
during normal maturation. Leukemic cells frequently have a nuclear chromatin 
pattern that is finer and more immature appearing than that of a corresponding 
normal cell. They also demonstrate multiple (three to five or more), often large, 
nucleoli that persist even as the cell cytoplasm matures. 
 
HISTOCHEMISTRY 
12
  
Histochemical stains help confirm the granule content of a malignant cell line. The 
peroxidase and specific esterase stains detect the primary granules of myeloid 
cells. In contrast, the nonspecific esterase stain detects esterase activity in 
monocytes and is only weakly positive in immature myeloid cells. Both the 
alkaline phosphatase and periodic acid Schiff (PAS) stains give a strong reaction 
with mature granulocytes. The most commonly used stains are the following  
Peroxidase stain : 
This stain detects the myeloperoxidase enzyme contained in the primary granules 
of myeloid cells. In the presence of hydrogen peroxide, myeloperoxidase releases 
free oxygen that can then be detected with benzidine or 3-amino-9-ethyl carbazole. 
The latter reagent gives a reddish-brown reaction product, whereas the benzidine 
reagent produces a bluish-black product. Myeloperoxidase is abundant in nearly all 
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mature and immature myeloid cells and is also present in monocytes to a small 
extent. Recently, it has become possible to detect myeloperoxidase using a 
monoclonal antibody and flow cytometry. The increased sensitivity of this method 
has proved very useful in identifying even very immature myeloid leukemias that 
appear to be peroxidase negative by histochemistry. 
Combined esterase stain : 
This stain uses two substrates, alpha naphthyl acetate and naphthol ASD 
chloracetate, to distinguish myelocytes from monocytes. The chloracetate esterase 
stain (specific esterase) identifies the primary and secondary granules in myeloid 
cells. It gives a negative or very weak reaction in monocytes. Furthermore, it is 
resistant to treatment with sodium fluoride. The alpha naphthyl acetate stain 
(nonspecific esterase) produces a strong reaction in monocytes, which is positive to 
a varying degree in mature and immature myeloid cells. The monocyte reaction is 
inhibited by sodium fluoride. 
Periodic acid Schiff (PAS) : 
This stain involves the oxidation of carbohydrates by periodic acid to aldehyde 
products. Mature myeloid cells stain intensely red; myeloblasts are usually 
negative. The Periodic acid Schiff (PAS) stain is useful in separating AML from 
acute lymphocytic leukemia; lymphoblasts can show heavy blocklike staining.
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STAINS M0 M1 M2 M3 M4 M5 M6 M7 
MPO _ + + + +/- _ +/- _ 
SUDAN BLACK B _ + + + +/- _ +/- _ 
NSE _ _ _ _ + + _ _ 
PAS _ _ _ _ _ + + _ 
 
IMMUNOPHENOTYPING 
 
They are most useful in distinguishing myeloid from lymphoid leukemias and in 
helping determine the lineage of the myeloid leukemias. The immunologic 
classification of an acute leukemia does not always correlate with the morphologic 
appearance. For example, cells expressing monocyte markers may or may not have 
a morphology that suggests monocytic leukemia, and the degree of maturation 
suggested by the surface markers may not match morphologic features such as 
cytoplasmic granules and nuclear chromatin. Myeloid leukemias can also show 
lineage infidelity in that they express markers that are normally not present on the 
same cell or because they lack markers that should be present on the cells of a 
given lineage. Finally, it is common to find a heterogeneous expression of markers 
within the leukemic population. A patient who has nearly 100% blasts by 
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morphology may show only 50% blasts by marker studies. This condition is 
usually owing to variations in the intensity of expression of the markers on the 
cells but could reflect true clonal diversity within the leukemic population. 
 
Immunologic markers on myeloid cells and leukemias. 
CD Other Names Normal Cells Utility in AML 
13 My7 Mono and myeloid Distinguish AML from ALL 
14 My4 Mature monocytes Monocytic leukemias 
15 My1 Mono and myeloid Distinguish AML from ALL 
33 My9 Mono and myeloid Most consistent marker in AML 
34 My10 Progenitor cells only Most primitive marker, poor prognosis 
41 GPIIb/IIIa Megakaryocytes Megakaryocytic leukemia 
42 GPIb Megakaryocytes Megakaryocytic leukemia 
45 HLE All leukocytes Frequently decreased in leukemias 
117 CKit Progenitor cells Expressed with CD34 in most AML 
HLA-DR Mono and myeloid Nearly always present on AML and ALL 
Glycophorin Erythrocytes Erythroleukemia 
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Cytogenetics 
It helps in deciding the appropriate therapy .It helps in finding the particular 
subtype of AML. It plays a major role in estimating the prognosis. In 50–60% of 
cases the cytogenetic evaluation is normal. Both blood and marrow specimens 
should be collected cytogenetic studies. Chromosomal analysis should be 
performed using high resolution banding techniques in order to identify common 
translocations.  This type of information is particularly useful in the case of very 
immature leukemias in which it can be difficult to distinguish between myeloid 
and lymphoid lineage. The distinctive phenotype and genotype of the malignant 
cell line can also be used once the patient enters remission to detect relapse and 
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new mutations at the earliest possible time. The new WHO/FAB classification of 
the myeloid leukemias  recognizes cytogenetic abnormalities as a key factor in the 
classification of AML. In fact, even in patients with non-diagnostic morphologies 
and few blasts, the presence of one of these distinctive mutations will make the 
diagnosis. 
 
RISK STATUS BASED ON VALIDATED CYTOGENETICS ABNORMALITIES13
 
Favourable risk    
 Translocation between the chromosome 8 and 21: FAB M2;   
Fused  genes  are  acute myeloid leukaemia 1 protien (AML1)and ETO. 
 Translocation or inversion in chromosome 16 14: FAB M4Eo;  
fusion gene CBFb/MYH11. 
 t(15;17)(q21;q11): FAB M3; 
fusion gene PML and RARa.  
 Translocation between the chromosome 11 and 17; 
 fusion gene PLZF and RARa. 
 Translocation between the chromosome 5 and 17; 
fusion gene NPM and RARa. 
 Translocation between the chromosome 11 and 17; 
 fusion gene NuMA and RARa. 
Intermediate risk  
 Normal karyotype: any FAB type 
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 + 8: any FAB type 
 abnormal 11q23;fusion gene MLL. 
 Others: del(9q); del(7q); +6; +21; +22; –Y and 3–5 complex abnormalities 
plus other structural or numerical defects not included in the 
good risk or poor risk groups. 
Poor risk  
 –5/del(5q): any FAB type 
 –7/del(7q): any FAB type 
 Complex karyotypes (>5 abnormalities) 
Others: t(6;9)(p23;q34); t(3;3)(q21;q96); 20q; 21q; t(9;22); abn 17p.  
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Molecular Markers 
Molecular markers are more important in the cases having normal cytogenitics. 
Many molecular markers with implication on prognosis have been discovered so 
far. Few common molecular markers with prognostic implictions are FMS-like 
tyrosine kinase 3 and nucleophosmin mutation . 
RISK STATUS BASED ON VALIDATED MOLECULAR 
ABNORMALITIES
 
Favourable risk   
 Normal cytogenetics 
Nucleophosmin 1 mutation in the absence of  ITD mutations in Fms-like tyrosine 
kinase 3 (FLT-3)
15,16
  
  OR 
Isolated biallelic CEBPA mutation 
17-19
 
Intermediate risk 
 Translocation between chromosome 8 and 12, inversion or  translocation in 
chromosome 16 with c-KIT mutation 
 
Poor risk 
 Normal cytogenetics  
 
 ITD mutations in Fms-like tyrosine kinase 3 (FLT-3) 19 
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OTHER LABORATORY STUDIES 
 
The growth of the myeloid cell tumor mass is associated with several metabolic 
abnormalities. The serum lactic dehydrogenase (LDH) level is elevated in most 
patients without significant changes in other liver chemistries. An elevation mirrors 
the rate of growth and turnover of the leukemic cells. Another indirect measure of 
myeloid cell proliferation is the level of vitamin B12 binding proteins, specifically 
transcobalamin III. In patients with myelomonocytic or monocytic leukemia, a 
high tumor burden is associated with an increased excretion of muramidase 
(lysozyme) in urine. This process can result in potassium wasting and 
hypokalemia. Finally, up to 20% of patients may have an elevated serum uric acid 
level.
 
AML with recurrent genetic abnormalities 
These disorders have genetic abnormalities, the commonest being translocations 
which create fusion genes that regulate production of abnormal proteins. 
20 
Most common are: 
 Translocation between the chromosome 8 and 21: They are found in 5-10% of 
AML cases ,mainly in younger patients. Auer rods are commonly  present. 
Nucleoli are prominent. Blasts express CD13, CD34 and B-cell associated 
antigen like CD19. Prognosis is better, and this type corresponds to AML-M2 
(FAB).
21
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 Translocation or  inversion in chromosome16: This corresponds to M4 Eo. 
Bone marrow shows elements of both granulocytic (including myeloblasts) and 
monocytic differentiation (monoblasts, promonocytes and monocytes), 
combined with abnormal eosinophils showing large purple granules along with 
basophilic granules in a background of eosinophilic granules. WHO classifies it 
as AML irrespective of blast cell count.
22
 In this type blasts are CD13 and 
 
CD33 positive and also monocytic markers CD14, CD64 positive. Prognosis is 
good, they achieve longer complete remissions.
23 
 Translocation between chromosome 15 and 17: Acute promyelocytic leukemia  
 
– abnormal promyelocytes – hypergranular or hypogranular are present. 
 
This is equivalent to M3 or M3v in the FAB classification.
24 
 Numerous Auer rods 
are present (Faggot cells).This type is usually associated with Disseminated 
Intravascular Coagulation (DIC). Some cases contain a subset of blasts which are 
weakly positive for NSE, but MPO is strongly positive. CD 33, CD13, CD117 and 
CD64 are positive . Patients are sensitive to treatment with All-Trans Retinoic 
Acid (ATRA) and the prognosis with ATRA therapy is betterthan any other AML 
cytogenetic subtype. 
 
 Abnormality in q23 of chromosome 11:  Frequently seen in children 
 and represents 9% to 12% in them, and 2% of adult AML.
 
This type is positive for 
CD33, CD65, CD4 and HLA-DR and can be mistaken for M4 or M5 types. 
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AML with multilineage dysplasia 
This is a rare type of AML and demonstrates dysplasia in >50% of cells in 2 or 
more cell lines including megakaryocytes or a prior history of Myelodysplastic 
syndrome/Myeloproliferative neoplasm (MDS/MPN). Abnormal erythropoiesis is 
characterized by ringed sideroblasts, vacuolated cytoplasm and megaloblastic  
change. Abnormal megakaryocytes are small and have a single lobed nucleus.  
Granulopoiesis demonstrates lack of granules and bizarre segmented nuclei. This  
type of AML appears to represent 24-35% of all cases of AML.
25 
Therapy-Related acute myeloid leukemia 
This type of AML follows cytotoxic drugs or radiation. MDS occurs first with  
evidence of marrow failure. Two thirds of cases have multilineage dysplasia and  
25% develop refractory anaemia with excess blasts. Usually trilinear dysplasia is  
seen. One type develops following alkylating agents, another following  
topoisomerase II inhibitors such doxorubicin therapy. 
AML not otherwise categorized   
This classification depends on the morphologic and cytochemical characteristics of 
blasts and their degree of differentiation and includes the following. 
• AML, minimally differentiated (M0 in FAB classification) - blasts show no 
myeloid differentiation and are medium sized, have agranular cytoplasm, 
30 
 
round/oval/indented nucleus with 1-2 nucleoli. Cytochemically, <3% cells are 
MPO positive and confirmed by CD13, CD33 positivity.  
• AML without maturation (M1 in FAB classification) – Blasts>90% of bone 
marrow non-erythroid cells (NEC). MPO positivity is seen in >3% blasts. Less 
than ten percentage mature granulocytic or monocytic cells are present in the 
marrow. 
• AML with maturation (M2 in FAB classification) – Blasts form 20-89% of 
marrow  non erythroid cells and may show Auer rods and azurophilic granules. 
Mature 
granulocytic  cells more than ten percentage of non erythroid cells. Marrow  
monocytic  less than 20% of  non erythroid cells. The criteria for acute  
myelomonocytic leukemia will not be fulfilled.  
Acute promyelocytic leukemia – abnormal promyelocytes – hypergranular or  
hypogranular are present. This is equivalent to M3 or M3v in the FAB  
classification. Numerous Auer rods are present (Faggot cells).This type is usually  
associated with Disseminated Intravascular Coagulation (DIC). Some cases contain  
a subset of blasts which are weakly positive for NSE, but MPO is strongly positive.  
CD 33, CD13, 
• Acute myelomonocytic leukemia (M4 in FAB classification) – Blasts >20% of 
marrow NEC. Both neutrophilic and monocytic cells and their precursors are 
present. Each  of them more than twenty percentage of the marrow cells . Blasts  
are MPOpositive. 20-80% of the cells are NSE positive. M4Eo is a distinct entity  
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with eosinophilic differentiation, demonstrating a specific genetic marker inv 16 
and such cases have a good prognosis. The marrow shows promyelocytes, 
myelocytes with larger eosinophilic/ purple violet granules, along with blasts. 
• Acute monoblastic and acute monocytic leukemia (M5a and M5b in 
FABclassification) –In monoblastic type  more than eighty percentage of the cells 
are monoblasts while in monocytic type  more than eighty percentage  of the cells 
are monocytic, mostly monocytes and promonocytes. 
• Acute erythroid leukaemia has 2 subtypes- 
M6a- Blasts are >20% of the NEC and erythroid cells are >50% of the 
nucleated cells of the marrow. There is multilineage dysplasia with 
megaloblastic and dysplastic erythroblasts.
26 
M6b (Pure erythroid leukemia) – erythroblasts constitute more than eighty  
percentage of marrow cell. Erythroblasts  have agranular basophilic cytoplasm.  
Round nuclei with fine chromatin and 1-2 nucleoli. 
• Acute megakaryoblastic leukemia (M7) – In this type, more than fifty percentage 
of megakaryocytic precursors seen in marrow. The megakaryoblasts are often 
pleomorphic, having basophilic, often agranular cytoplasm that has pseudopod and 
bleb formation.Circulating micromegakaryocytes are seen. 
• Acute basophilic leukemia- In this type, the primary differentiation is to 
basophils and the blasts are of medium size with a high nucleus to cytoplasm ratio.  
Coarsely granular basophilic cytoplasm  is seen. 
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• Acute panmyelosis with myelofibrosis- Acute panmyeloid proliferation with 
accompanying fibrosis of marrow. They do not meet the criteria for acute myeloid  
leukemia with myelodysplasia related changes. 
Acute Leukaemias of Ambiguous Lineage 
These are the cases in which myeloid/ lymphoid origin is not made out .  
In less than 4% of cases of leukemia, tests currently available:  
(1) cannot determine whether the blasts have a myeloid or lymphoid origin (acute 
undifferentiated leukemia) 
 (2) indicate two populations of cells, each having a distinct lineage from myeloid 
or T or B lymphocytes (acute bilineal leukemia) 
(3) indicate that the blasts individually have markers of two or three lines of 
myeloid, T lymphocytes, and B lymphocytes (acute biphenotypic leukemia). In 
acute undifferentiated leukemia, the blasts lack any distinguishing characteristics, 
whereas in the bilineal and biphenotypic forms, the leukemic cells may resemble 
lymphoblasts, myeloblasts,or monoblasts. 
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BIPHENOTYPIC LEUKEMIA DIAGNOSIS 
It is necessary to score more than 2 points from two separate lineages in order to 
classify a case as biphenotypic.
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 Special cytologic , clinical,and laboaratory features of subtypes of AML 
Acute myeloblastic leukemia (M0,M1,M2) 
Cytologic Features 
1. 20 to 90% blasts cells are seen. Distinct nucleolus and fine reticular nucleus are  
 
seen. Auer bodies are rare. 
 
2. Blasts are positive for MPO , chloroacetate esterase and negative for NSE.  
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AML M0 
 
 
 
MYELOPEROXIDASE NEGATIVE STAINING AML M0 
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AML M1 MYELOPEROXIDASE POSITIVE STAINING 
 
 
Special Clinical Features 
1. Most common in adults and  infants. 
 
2. Three subtypes are included in acute myeloblastic leukaemia. 
3.  
Special Laboratory Features 
1. Acute myeloid leukaemia protein 1 and FLT3/ITD  mutations occur in about 
20–25% of cases.   
2. M0 subtype is CD34 CD13 or CD33positive.  
3. CD13 and CD33 are expressed in M1.Positive for myeloperoxidase by 
cytochemistry.  
4. M2 AML is associated with translocation of chromosome 8 and 21. 
5. Complex cytogenetic abnormalities are common. 
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AML M0 Positive immunostaining CD34 
  
 
Acute promyelocytic leukemia (M3)  
Cytologic Features 
1.Abnormal promyelocytes are present. Nucleus is kidney shaped . 
2.Hypergranular acute promyelocytic  leukemic cells are called faggot cells. A 
variant of M3 has microgranules.
 27-28 
3.Intensely positive for MPO.  
4. Branched auer rods can be seen. 
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A faggot cell (bottom left) 
 
Special Clinical Features 
1. Usually in adults.  
2. Hypofibrinogenemia and hemorrhage are common.
30 
3. Blasts mature in response to ATRA.  
Special Laboratory Features 
1.Translocation between chromosome 15 and 17 seen. 
2. Cells are HLA-DR negative.  
Acute myelomonocytic leukemia (M4, M4Eo)  
Cytologic Features 
1.Blast population consist of both myelobasts and monoblasts.  
2.MPO, Sudan Black B, chloroacetate esterase, and NSE positive cells. 
38 
 
3. M4Eo variant has marrow eosinophilia.  
    GUM INFILTERATION  
 
MYELOBLAST AND MONOBLASTS SEEN 
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Special Clinical Features  
1 Extramedullary infiltration is common.
31 
2. Mildly elevated serum and urine lysozyme.  
Special Laboratory Features 
1. inversion or translocation of chromosome 16 is associated with eosinophilic 
variant. 
Acute monocytic leukemia (M5) 
Cytologic Features 
1. Large blasts  with low N:C ratio lower than myeloblast  with fine granular 
cytoplasm. 
2. NSP +ve inhibited by NaF 
3. Auer rods are rare 
40 
 
 
Special Clinical Features 
1. Seen in children or young adults.  
2. Extramedullary involement is commonly seen. 
 
3. Disseminated intravascular coagulation can occur.  
4.Lymphadenopathy, gum infiltration and central nervous system infiltration can 
occur. 
Special Laboratory Features 
1Translocation of chromosome 4 and 11 are common in infants.  
2.Rearrangement of q11;q23 very frequent. 
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Acute erythroid leukemia (M6)  
Cytologic Features 
1.Abnormal erythroid cells are seen.
32
  
AML M6- Multinucleated erythroblast has megaloblastoid chromatin  
 
Special Clinical Features 
1. Pancytopenia common at diagnosis.  
Special Laboratory Features 
1. Cells reactive with antihemoglobin antibody.
33
  
Acute megakaryocytic leukemia (M7)  
42 
 
Cytologic Features 
1.Bleb forming blasts are seen.  
2. Megakaryoblasts are seen with dense ,homogenous chromatin and irregular 
cytoplasmic border. 
AML M7 – BIG BIZARRE PLATELETS 
 
Special Clinical Features 
1. Usually presents with pancytopenia.  
2. Markedly elevated serum lactic dehydrogenase levels.  
3.Intense myelofibrosis results in dry tap .
34 
4. Associated with Down syndrome.  
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Special Laboratory Features 
1. Antigens of  VWF, and gp Ib , IIb/IIIa , IIIa  on blast cells.  
2. Platelet peroxidase positive.  
Acute eosinophilic leukaemia  
Cytologic Features 
1. Cells containing eosinophilic granules and blasts are seen. 
Special Clinical Features 
1. Hepatospleenomegaly and  lymphadenopathy are present.
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Special Laboratory Features 
1. Cyanide-resistant peroxidase stains eosinophilic granules.
36
  
2. Charcot Leyden crystals can be found in infiltrated sites. 
Acute basophilic leukaemia  
Cytologic Features 
1.Cells with basophilic granules mixed with blasts are seen.   
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Special Clinical Features 
1. Hepatospleenomegaly present. 
2. Urticarial rash, headaches, GIT symptoms are present.  
Special Laboratory Features 
1. CD11b+ve, CD9+ve,CD123+ve,CD25+ve.
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2.Cells are +ve for toluidine blue. 
3.Histamines in  urine and blood are high. 
Acute mast cell leukaemia  
Cytologic Features 
1. Granular mast cells are seen. 
Special Clinical Features 
1.Patient may present with the complaints of flushing of face, fever ,pruritis,and 
headache. 
2.Peptic ulcer, bone pain, diarrhea are common . 
3.Hepatospleenomegaly is commonly present. 
4.Hemorrhagic manifestations may be present. 
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Special Laboratory Features 
1. CD117+ve,CD13+ve, CD68+ve, CD33+ve are positive.
38
  
2. Hyperhistaminemia and hyperhistaminuria.   
3. Positive staining for tryptase  
4.Serum tryptase elevated.  
 
An important element in diagnosing AML is the speed of the workup. This is 
especially true when AML presents as a precipitous illness in an otherwise healthy 
young adult, because successful management depends on the early initiation of 
appropriate chemotherapy. The time element is less important in patients who 
gradually evolve from a myeloproliferative or myelodysplastic disease into AML. 
In this situation, it can be to the patient's advantage to delay therapy until it is 
absolutely necessary. 
It is very important to determine whether the AML is secondary to some other 
factor such as previous chemotherapy or radiation exposure. AML is the most 
common form of secondary malignancy following previous tumor therapy. In 
addition, the incidence of AML as the final outcome in patients with 
myeloproliferative/dysplastic diseases, such as RAEB (refractory anemia with 
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excess blasts), polycythemia vera, and myelofibrosis may be increased by 
treatment with specific chemotherapeutic agents. Both aplastic anemia and AML 
have also been associated with benzene exposure. These relationships are 
important since secondary AML generally carries a worse prognosis. The patient 
may be slow to achieve remission, relapse rapidly, or fail to recover normal 
hematopoiesis following chemotherapy. 
Because of the need for a rapid workup and treatment decision, the initial 
classification of a myeloid leukemia is most often based on cellular morphology 
and histochemical staining, using the old FAB system . The key decision points are 
the following: 
• Does the patient have acute myelocytic versus acute lymphocytic leukemia? 
• To which FAB category does the patient belong? 
Therapy can be and should be initiated based on this information. It is unnecessary 
and unwise to wait for the results from immunophenotyping and chromosomal 
analysis. Although these results may affect long-term management and prognosis, 
they are not important in guiding the initial treatment decision. 
The patient should also be routinely evaluated for a coagulopathy. This process is 
very important in patients with acute promyelocytic leukemia (M3). Many of these 
patients present with ongoing DIC and a severe bleeding tendency, which can 
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worsen in the early phases of treatment. A full coagulation profile including a 
platelet count, PT, PTT, thrombin time, fibrinogen level, split product or D-dimer 
level (or both)  should be measured prior to initiating chemotherapy. 
The final classification of the patient's leukemia will reflect the studies of 
morphology, immunophenotype, and cytogenetics, and the relationship to 
preexisting preleukemic states . 
PROGNOSTIC FACTORS IN AML 
FACTORS Factor Favorable Unfavorable 
 
Age 
 
<45 y, <2 y >60 y 
ECOG PS 0–1 >1 
 
Leukemia De novo Antecedent hematologic 
disorder 
Infection Absent Present 
 
Prior chemotherapy 
 
No Yes 
Leukocytosis <30,000/mm
3 
>50,000/mm
3 
 
Platelet count 
 
>30000/mm
3 
<30000/mm
3 
Serum LDH Normal  Elevated  
Extramedullary disease Absent  Present  
CNS disease Absent  Present  
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Cytoreduction 
 
Rapid  Delayed  
 
FACTORS 
 
 
 
Factor Favorable 
 
Unfavorable 
 
Eosinophils Present  Absent  
Megaloblastic erythroids Absent  Present  
Dysplastic megakaryocytes Absent  Present  
FAB subtypes M2, M3, M4 M0, M6, M7 
Blast % < 5% blasts on day 14 
marrow predicts for 
complete remission 
>70 % 
  
Treatment of  AML (except M3) 
 
General Guidelines 
Reliable vascular access is essential and usually requires placement of an in-
dwelling catheter The patient should be hydrated and receive allopurinol 300 to 
600 mg/day by mouth to prevent hyperuricemia as tumor cells are lysed. Serum 
electrolytes and CBCs need to be monitored on a daily or every-other-day basis. In 
those patients who are at risk for DIC, a full coagulation profile should be 
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measured daily for the first several days of chemotherapy. Hypofibrinogenemia 
(fibrinogen less than 100 mg/dL) should be corrected by infusion of 
cryoprecipitate, whereas marked prolongations of the PT and PTT may be 
corrected with fresh frozen plasma. Promyelocytic leukemia patients may benefit 
from being prophylactically anticoagulated with heparin using a moderate-dose 
protocol . If bleeding is life-threatening, the patient should be treated with platelet 
transfusions and infusions of cryoprecipitate to correct hypofibrinogenemia 
(fibrinogen levels less than 100 mg/dL).In the absence of severe cardiovascular 
disease, the hematocrit should remain in the vicinity of 25 to 30% to decrease the 
frequency of red blood cell transfusions. Platelet transfusions should only be given 
when the platelet count falls below 10,000/µL in the patient with little or no 
bleeding, or 20,000/µL if the patient has significant mucous membrane bleeding or 
tends to bleed from venipuncture sites. 
The treatment of ongoing infection must be very aggressive, and potential sources 
of infection should be eliminated. For example, infected teeth should be pulled, 
abscesses drained, and foreign bodies such as infected intravenous catheters 
removed and replaced. Good nursing care of the mouth, skin, and rectum is very 
important. Oral prophylaxis to prevent infection using an oral fluoroquinolone such 
as ciprofloxacin can be used. It is well tolerated and preserves the anaerobic 
gastrointestinal flora, thereby avoiding the problem of fungal overgrowth in the 
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intestinal tract. It also appears to be effective in reducing the frequency of systemic 
infections with gram-negative bacteria. 
Prophylactic antifungal therapy with nystatin, miconazole, and ketoconazole has 
been used in the past to prevent yeast colonization of the gastrointestinal tract as a 
source for systemic candidiasis. Newer antifungals, including fluconazole, may be 
more effective. Empiric antiviral therapy has also been recommended.  
Empiric Antibiotic Therapy 
If patients are not already febrile at the time of diagnosis, they soon become febrile 
with treatment. They should have thorough cultures to identify specific organisms. 
But even before a specific site of infection is identified, they need to receive 
empiric antibiotic therapy. The choice of antibiotics will depend to some extent on 
what organisms are seen in each institution. The usual approach is to provide 
broad-spectrum coverage for both gram-negative and gram-positive organisms. A 
popular combination of antibiotics for this purpose is an aminoglycoside 
(gentamicin, tobramycin, or amikacin) together with an antipseudomonal penicillin 
(carbenicillin, ticarcillin, mezlocillin, or piperacillin).
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Induction :Age <60 y 
 Cytarabine(standard dose) 100-200 mg per m2 for 7 d plus idarubicin 12 mg 
per m
2
 or daunorubicin 90 mg per m
2
 for 3 days (category 1)
39
.  
 Cytarabine(standard dose)   plus daunorubicin 60 mg per m2 for 3 d and 
cladribine 5 mg per m
2
 for 5 d (category 1). 
 Cytarabine (High dose) 2 g per m2 every 12 hours for 6 d or 3 g per m2 every 
12 hours for 4 d  plus  idarubicin 12 mg per m
2 
or daunorubicin 60 mg perm
2
  
for 3 d
 
(1 cycle) (category 2B).  
 Predictable complications such as anemia, thrombocytopenia, a 
coagulopathy, or infection should never delay therapy since they are unlikely 
to improve until a remission is obtained. They should be treated with 
appropriate transfusions and antibiotics at the same time the chemotherapy is 
begun. The goal of therapy is to ablate the leukemic cell line and allow 
normal progenitor cells to repopulate the marrow. This process will require a 
period of marrow aplasia and marked granulocytopenia that can extend for 1 
to 4 weeks or even longer.  
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A careful examination of the patient, repeated chest x-ray, and blood cultures 
should be obtained with each episode of chills and fever, and the clinician should 
look for a drug-resistant bacterium or fungus.  
RISKSTATUS   (cytogenetics 
and molecular 
abnormalities) 
POST REMISSION THERAPY 
Better risk  
 
Cytarabine (high dose)  3-4 cycles (category 1)/ or 
cytarabine(high dose) 1-2 cycles followed    by 
autologous Hematopoietic stem cell 
transplantation (category 2B) 
Intermediate risk  
 
Hematopoietic stem cell transplantation or 
cytarabine(high dose)  x 3-4 cycles 
Poor risk  Matched sibling or alternative donor HSCT 
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POST INDUCTION THERAPY 
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EVALUATION AND TREATMENT OF CNS LEUKEMIA 
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AGE>60 yrs 
Low-intensity therapy may be more appropriate for elderly patients or relatively 
unfit patients with comorbidities (subcutaneous cytarabine, 5-azacytidine, 
decitabine). Based on the ECOG performance status low intensity therapy or 
standard chemotherapy is chosen.
 
Treatment of APL (M3) 
Induction 
All trans retinoic acid is used .  It is  given with daunorubicin or idarubicin.
 
Another option is ATRA + arsenic trioxide.
40
 Patient who can not tolerate 
cytotoxic therapy can be given the above regimen. Arsenic trioxide  dose given is  
0.15 mg/kg/day IV till remission occurs plus  ATRA 45 mg/m
2
/day in 2 divided 
doses.
41 
Consolidation  
Post-remission treatment drugs options include:  
 Anthracycline + All-trans-retinoic acid  for a few cycles.  
 Anthracycline + cytarabine for at least 2 cycles . 
 Arsenic trioxide for 2 cycles followed by All-trans-retinoic acid + an 
anthracycline for 2 cycles . 
 All-trans-retinoic acid + Arsenic trioxide for several cycles  
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Maintenance  
ATRA for at least one year. Sometimes low doses of the chemotherapy drugs 6-
mercaptopurine and methotrexate are given as well.
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ACUTE MYELOID LEUKEMIA RESPONSE CRITERIA  
43-45 
Morphologic leukemia free state 
 Bone marrow aspirate containing less than five percentage of  myeloblast . 
 No extramedullary disease. 
 Absence of Auer rods . 
Complete remission 
Morphologic CR  
 PMN >1000/mm3 
 Platelets count >100,000/mm3  
 No residual evidence of extramedullary disease 
 Patient independent of transfusions 
Cytogenetic complete response   
 Previously abnormal cytogenetics becomes normal. 
 
Molecular complete response- 
 RT-PCR negative 
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Partial remission 
 There is a 50% reduction  in the % of blasts to 5% - 25% in the BMA. 
 
 Blood count is normal. 
 
Detection of minimal residual disease  
Few leukemic cells which left after treatment which could not be detected by 
routine bone marrow examination is called minimal residual disease. PCR test and 
multiparameter flowcytometry are considered  the gold standard for MRD 
monitoring in AML.. 
  
 
HSC, normal hematopoietic stem cell, LSC, leukemic stem cell 
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Detection of MRD in consecutive  samples from a patient in still remisssion 
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Detection of MRD in consecutive samples from a patient with relapse  
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Sequential monitoring MRD can accurately predict relapse, thus opening the way 
to risk-directed therapy . MRD can be used to guide the risk adapted treatment.
46 
MRD-negative remission leads to prolonged duration of CR. Thus achieving 
MRD-negative remission represents a gold standard.
 47
 Recently, a trial of 
prospective MRD-driven therapy has shown improvement of outcome in high-risk 
patients.
48 
Hence intensified therapy can be given to the patients with MRD during 
clinical remission.
49
  
Aberrant phenotype in AML 
Types: 
 
 Co-expressed lymphoid lineage markers. 
 
 Asynchronous antigen expression : Mature antigens are co-expressed with  
 
immature antigens. 
 
 Overexpressed antigens50 
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Flowcytometry  
It is a technology which measure and analyze multiple  physical  parameter of 
cells. Relative fluorescence intensity, granularity ,size and internal complexity are 
the physicical characteristics of the cell which are measured and analyzed. The 
cells when flowing  in a fluid stream cause the scattering of the laser light. These 
characteristics are coupled to electronic coupling system. 
It has three main systems: 
• The fluidics system:  
Fluid stream in  which the cells flow . 
• The optics system:  
The optical filters and laser beam which illuminates the cells. 
• The electronics system : 
Electronic system converts the light signals are into electronic signals which can be 
processed by the computer.  
Light Scatter 
There are two types of light scatter: forward scattered light (FSC)and side scattered 
light(SSC) 
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63 
 
 
Fluorescent  dye  conjugated with a monoclonal antibody against the individual 
antigenic surface markers of the cell can be used to identify blast population . 
Gating 
Graphical boundary can be made to define the blast population by gating.  
Differentiation of cell size can be made out by FSC/SSC gating. 
CD45/side scatter (SSC) gating 
Precursor cells and blasts have low expression of CD45.CD45 is highly expressed 
by lymphocytes and monocytes. Hence the blast population can be easily 
identified.  The conventional Forward scatter /SSC gating miscalculates the 
leukemic cell % . Thus CD45/side scatter (SSC) gating 
(1) Clearly distinguishes leukemic blast cells from normal cells. 
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(2) Exclusion of immunophenotyping of normal cells.  
(3) Identification of heterogeneous blasts.  
  
 
Morphological study of leukemic cells with cytohistochemistry and  cytogenitics 
study can diagnose leukemias. Few cases cannot be diagnosed by the above 
methods. Such cases can be diagnosed by immunohistochemistry by 
flowcytometry. Analysis of multiple special characteristics of single cells can be 
done rapidly. The information obtained is both qualitative and quantitative.  
One of the most important use of flowcytometry is immunophenotyping. Acute 
leukemias can be accurately diagnosed and classified. Prognostic associations can 
also be made out 
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Association between the genetic abnormalities in AML and their 
immunophenotype  
 AML with t (8;21): 
 
 Khoury et al, 2003 
 
They are strongly positive for MPO, HLADR, CD34, and CD13 . CD33is weekly 
expressed. CD19, cCD79a and CD56 are frequently observed. CD56 expression is 
associated with poor prognosis in AML.
51
  
 Chen SW et al ,2008  
 
Co-expression of CD19 and CD56 is found in higher frequency in AML with 
translocation between chromosome 15 and 17.
52 
 AML with translocation or inversion in chromosome 16: 
 
Dunphy, 1999; Medeiros et al, 2010 
CD2 is the most common lymphoid associated antigens expressed. Asynchronous 
antigen expression is the most common type of aberrant phenotype found.
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 APL with t(15;17):  
 
 Paietta et al, 2004 
 
HLA-DR and CD34 are poorly expressed. There is a strong expression of CD117. 
20 % of the patient express CD56 . CD65 and CD 15 ,which are granulocytic 
markers are not expressed.
54 
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 NPM1 mutations 
 
 Falini et al, 2005 
 
NPM1 mutations are seen in about 30% of adult AML. If there is no internal 
tandem duplication in FLT3, it is associated with a good prognosis .They are CD34 
–ve and CD33+ve.55  
 AML with mutated CEBPA. 
 
  Haferlach et al, 2009 
 
The most common aberrant antigen expression is CD7.
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CD7  
In most of the studies, expression of CD was associated with poor outcome.  
Chang et al, 2007
 
37% of AML were CD7 positive. CD7  expression was an independent risk factor. 
They were associated with shorter disease free survival .
57 
Tiftik et al, 2004; Suzuki et al, 2010
 
CD7 positive CD56 positive  AML has a characteristic clinical feature. They 
present most often with lymphadenopathy with or without a mediastinal mass 
,extramedullary involvement .  They don’t repond well to therapy.58,59 
Veronica et al, 2008 
Expression CD7 is more commonly seen in association with FLT3/ITD mutation.
60 
67 
 
CD 56  
Raspadori et al, 2001, 2002
 
CD56  is expressed by natural killer cells. Normal myeloid cells don’t express 
CD56. It associated with  bad prognosis like incomplete response to therapy and 
poor survival .
61
  
Yang et al, 2007
 
Extramedullary infiltration is more common with CD56 expression . AML with 
t(8;21) usually has a favourable prognostics but if CD56 is expressed it is poor. 
62
 
Alegretti AP, Bittar CM, Bittencourt R, Piccoli AK, Schneider L, Silla LM, et 
al.,2011 
Eight cases (16.7%) were CD56 positive without correlation to age or gender. The 
highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death 
rate during induction was not significantly different between patients with and 
without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients 
that expressed CD56 had significantly lower overall survival than those who did 
not (mean 4.0 months vs. 14.5 months; p-value = 0.03). 
 Elyamany, G. et al (2013).  
The prognostic significance of selected markers of cells is well known, CD7 and 
CD56 expression at diagnosis has been associated with low remission rates and 
biological aggressiveness in a significant proportion of acute leukemias . 
68 
 
Incidence  of aberrant phenotypes  
Zheng et al, 2008.
 
The leading lymphoid associated  antigen was CD7(20.5%) followed by CD2, 
CD19 and CD22.  Aberrant markers like CD8, CD5, CD10, CD20, CD3 and 
cCD79a were detected in lower than 5% of AML cases.
63 
Jahedi et al ,2014.
 
Aberrant phenotype was seen in 57.1% of AML cases. CD7 and CD2 were the 
most frequent lymphoid associated antigen found in the sample cases.CD7 was 
expressed in 72.7% of cases in M1 and 28.5% in M2 . CD7 was not expressed in 
any of the M3 and M4 cases. CD2 was most commonly seen in M1 followed by 
M2 and M3. CD2 was not seen in M4.
64 
Jha R et al, 2013.
 
Aberrant phenotype were seen in about 35% of  cases. M7 did not show any 
aberrancy. All M0 cases had aberrant phenotype and about  51.9% in . Lymphoid 
associated antigen in descending order are  CD 7(20%) ,CD 4(14%) ,CD 19(8%).
65 
Azza H. El-Sissy et al,2006. 
 
CD9 (29.4%)  was the leading expressed aberrant antigen followed by CD7,CD19, 
CD4 and CD22.
66
 But  according to Shen et al., Bahia et al., John et al., CD7 was 
the most common aberrant antigens associated with AML.
67,68 
 
69 
 
Nahla AB Abdulateef et al,2014.
 
Aberrant phenotype was detected in 67.5% of AML cases. There were no 
correlation between aberrant phenotype and prognosis but AML cases expressing 
two or more lymphoid associated antigens showed a lower median relapse free 
survival than those positive for a single aberrant antigen . CD7 was associated with 
an unfavorable cytogenetic pattern (p=0.046).
69
  
Bahia et al,2001
 
A very high % of aberrant phenotypes , about 88.6% was found in the AML cases.  
Lymphoid associated antigen expression was about 34.3% . Asynchronous aberrant 
phenotype (82.4%) was the most common. CD7 was the most frequent lymphoid-
associated antigen. The most frequent  asynchronous aberrant phenotype was 
CD117
+
 CD34
+/-
 CD11c
+
(67.6%) and CD117
+
CD34
+/ 
CD15
+
  (61.7% ) of the 
cases, respectively. CD117
+
CD34
+/ 
CD15
+
 phenotype was associated with good 
phenotype a relevant association with clinical prognosis.
70
  
Launder et al,1996.
 
Aberrant phenotype was seen in 22% AML cases. CD7(44%), CD2(38%), and 
CD5(25%) ,CD19(13%)  and CD20(6%)  were expressed. They suggested that 
expressed aberrant antigens CD7, CD5, and CD2 in otherwise straightforward 
AML should not be considered as  lymphoid lineage commitment .
71 
 
70 
 
 
Dexler HG et al,1993.
 
CD4 and CD7 antigens were expressed in 24% and 15% of AML cases 
respectively. CD7+AML appeared to be associated with poor prognosis.
72 
Arber et al ,1996.
 
CD79a is a B lymphocyte  marker. CD79a  was expressed by 5% of all non-APL  
AMLs and 90% of all APL studied. All APL had the characteristic t (15;1 7) 
(q24;q21). CD79a is commonly expressed in association with t (15;17) AML.
73 
Aberrancies and prognosis in AML 
Immunophenotypic aberrancies have been explored to predict treatment outcome 
in AML. The results are not unequivocal. 
 Some studies reported an adverse prognostic association with a multitude of 
markers (cytTdT, CD7, CD9, CD11b, CD13, CD14, CD33, CD34 and CD56), 
while others failed to show any association between immunophenotype and 
treatment outcome (Lee et al, 1992; Raspadori et al, 1997; Venditti et al,1998; 
Ogata et al, 2001; Be´ne´, 2005).  
 Some antigens deserve further attention because their expression is related to 
survival. 
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INCIDENCE OF ABERRANT PHENOTYPES IN VARIOUS STUDIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY ABERRANT 
PHENOTYPE % 
Macedo A,1995 73% 
Launder et al,1996.
 
 
22 % 
Bahia.D.M et al,2001. 88 % 
Nahla AB Abdulateef et al,2014.
 
 
67.5% 
Azza H. El-Sissy et al,2006.
 
 
47% 
Jha R et al, 2013.
 
 
35% 
Naghmana Mazhar et al.2013 38% 
Jahedi et al ,2014.
 
 
57.1% 
Bhushan, Bharat, et al 2010 49% 
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MATERIAL AND METHODS 
SELECTION OF CASES 
The study conducted on freshly collected samples from 35 newly diagnosed acute 
myeloid leukemia patients . Acute myeloid leukemia was confirmed by bone 
marrow  aspiration / biopsy  and peripheral blood smear  based on the morphology 
and immunophenotyping. 
STUDY CENTRE  
Institute of internal medicine and  Department  of  hematology, 
Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai 
DURATION OF THE STUDY 
6 months, from Feb 2014 to July 2014. 
STUDY DESIGN 
Cross sectional study 
SAMPLE SIZE 
35 patients 
DATA COLLECTION AND METHODS 
35 cases of newly diagnosed AML were selected according to the selection criteria.  
 
Immunophenotyping was done on fresh bone marrow aspirate or peripheral blood  
 
samples. We applied Acute Leukemia Panel with these following CD markers:  
 
CD3, CD7, CD10, CD13, CD14, CD15, CD10, CD19, CD33, CD34,CD45,CD117.  
73 
 
 
CD marker was considered to be positive when more than 20% blast cells are  
 
positive. 
 
INCLUSION CRITERIA 
More than 20% myeloblast in bone marrow 
 
EXCLUSION CRITERIA  
1.Patient under treatment 
 
2.Relapsed AML patients  
 
INVESTIGATION DETAILS  
Immunophenotyping :  
Bone Marrow Samples  
Bone marrow Samples were aspirated from the iliac crest. The specimens were  
collected and drawn into EDTA tube. Samples were processed within 1hour. 
Peripheral blood samples  
The patients WBC count was adjusted at less than 10x 10³/ml. Each sample had 
more than mentioned count was diluted in order to reach the appropriate count. A 
specimen which contained any clout is excluded. A peripheral blood smear was 
prepared for microscopic assessment.  
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Bone marrow analysis  
A bone marrow smear was prepared for microscopic examination. Bone marrow 
aspirate was checked for clot existence, if any was present, it was disintegrated 
with wooden sticks. In order to remove any fat or proteins, the bone marrow 
sample was washed before the procedure. Washing instruction steps are: adding 
about 4-5 ml of 2% PBS to 1.5 -2 ml of bone marrow aspirate in test tube, 10 
minutes centrifuge at 2500 rpm , removing the supernatant and resuspending pellet 
with adequate volume of 2%PBS. These steps repeated two times  
 
Flow Cytometric Analysis of Acute Leukemia Cases  
Lysing and Staining:  
The reagents and capped polystyrene test tubes were provided by Beckman coulter. 
Ten microliters of fluorescein isothiocyanate (FITC) conjugated monoclonal 
antibody, 10μl of Phycoerythrin (PE) conjugated monoclonal antibody, 5μl of 
Allophycocyanin (APC) conjugated monoclonal antibody, and 5μl of Peridinin-
chlorophyll protein complex (perCP) conjugated monoclonal antibody was added 
to the tubes, afterward 100μL of whole blood / bone marrow  was in  added each 
tube. Monoclonal antibodies (Abs) used in this study included fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), or peridinin chlorophyll-protein (Per-
CP) ,Allophycocyanin (APC) labeled CD3, CD7, CD10, CD13, CD14, CD15, 
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CD10, CD19, CD33, CD34,CD45,CD117.The mixture was Vortexed tenderly and 
incubated about 45 minutes to 1 hour in the dark area at room temperature (20- 
25˚C). Two ml of 1X lysing buffer was added to incubated mixture. Then it was 
vortexed tenderly and incubated for 20 minutes in the dark area at room 
temperature again; after that Centrifuge at 500g for 5 minutes was done. 
The supernatant was removed. Subsequently 2-3 ml of washing buffer was added 
and centrifuged at 500g for 5 minutes and the supernatant was removed. 1 ml of 
1% cell fix (paraformaldehyde solution) was added and mixed completely, analysis 
can be done immediately or fixed cells can be stored at 2-8˚C until analysing them. 
Analysis was done by Beckman coulter brand flow cytometer. Samples vortexed 
thoroughly prior to acquisition. Abnormal populations were recognized by 
CD45/SSC gating, which was the base of calculating the positive rate of leukemia-
related antigens expressed on the abnormal cells. Antigen expression was 
considered to be positive 
when the percentage of positive blast cells was equal or greater than 20%. 
Similarly, aberrant phenotypes were defined when at least 20% of the blast cells 
expressed that particular phenotype. 
STATISTICAL METHODS  
Data were analyzed qualitatively and quantitatively by means of SPSS 14 
(Statistical package for social sciences 14). Frequency and descriptive analysis 
76 
 
were used in all statistical process. The statistical significance value was chosen to 
be below 0.05.  
SPONSORSHIP 
No  
CONFLICT OF INTEREST 
None  
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OBSERVATION AND RESULTS 
 
ABERRANT PHENOTYPE IN ACUTE MYELOID LEUKEMIA 
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Ly + /- AML IN MALES 
 
 
Ly + /- AML IN FEMALES 
 
 
 
 
74% 
26% 
 Ly- 
 Ly+ 
34%
66% 
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POSTIVE RATE OF INDIVIDUAL ANTIGEN IN Ly+AML 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIGEN NO OF POSITIVE / 
NEGATIVE CASES 
PERCENTAGE 
CD3 7/35 20% 
CD7 4/35 11.4% 
CD10 4/35 11.4% 
CD13 23/35 65.7% 
CD14 6/35 17.1% 
CD15 7/35 20% 
CD19 7/35 20% 
CD33 24/35 68.6% 
CD 34 24/35 68.6% 
CD117 16/35 20% 
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POSTIVE RATE OF INDIVIDUAL ANTIGEN IN Ly+AML 
 
 
ANTIGEN n % 
CD3 7/14 50% 
CD7 4/14 28.6% 
CD10 4/14 28.6% 
CD13 9/14 64.3% 
CD14 4/14 28.6% 
CD15 4/14 28.6% 
CD19 7/14 50% 
CD33 10/14 71.4% 
CD34 10/14 71.4% 
CD117 10/14 71.4% 
 
 
 
 
 
 
n = no of positive cases/no of negative cases 
% = positive percentage 
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LYMPHOCYTIC ANTIGEN EXPRESSION 
 
 
 
0 1 2 3 4 5 6 7 8
CD3
CD7
CD10
CD19
CD3 CD19
CD3 CD10
CD7 CD19
CD7 CD10
CD3 CD7 CD19
CD7 CD19 CD10
CD3CD19 CD10
CD3 CD7 CD10
CD19
NO OF CASES 
 
CD3 was the most common T cell antigen and CD19 was the most common B cell antigen expressed.  
 
82 
 
Distribution of aberrant T cell and B cell markers in AML 
 
T & B Ly+AML n Positive rate 
CD3 7/14 50% 
CD7 4/14 28.6% 
B Ly+AML 
 
CD19 7/14 50% 
CD10 4/14 28.6% 
Both T & B Ly+AML 
CD3,CD19 3/14 21.4% 
CD3,CD10 1/14 7.1% 
CD7,CD19 1/14 7.1% 
CD7,CD10 2/14 14.3% 
CD3, CD7,CD19 1/14 7.1% 
CD7,CD19,CD10 1/14 7.1% 
CD3,CD19,CD10 1/14 7.1% 
CD3,CD7,CD10,CD19 1/14 7.1% 
n = no of positive cases/no of negative cases 
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ASYNCHRONOUS ANTIGEN EXPRESSION IN AML 
 
 
ASYNCHRONOUS ANTIGEN 
EXPRESSION 
n POSITIVE RATE 
 
CD34+ CD15+ 7/35 20% 
 
CD34+ CD14+ 4/35 11.4% 
 
CD117+ CD34+ CD15+ 
 
4/35 
 
11.4% 
 
CD117+ CD34+ CD14+ 
 
4/35 
 
11.4% 
 
CD117+ CD34- CD15+ 
 
0/35 
 
0% 
 
CD117+CD34- CD14+ 
 
0/35 
 
0% 
 
CD117- CD34+ CD15+ 
 
3/35 
 
8.6% 
 
CD117- CD34+ CD14+ 
 
1/35 
 
2.9% 
 
n = no of positive cases/no of negative cases 
 
 
 Most common asynchronous antigen expression was CD34+CD15+. 
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Asynchronous antigen expression 
 
  
 
 
 
 
 
 
 
 
Most common asynchronous antigen expression was CD34+CD15+. 
 
0
1
2
3
4
5
6
7
8
  
CD34+ CD15+  
  
CD34+ CD14+ 
  
CD117+ CD34+ CD15+ 
  
CD117+ CD34+ CD14+ 
  
CD117- CD34+ CD15+ 
  
CD117-CD34- CD14+ 
NO OF 
CASE 
Asynchronous antigen expressed 
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CORRELATION  OF  IMMUNOPHENOTYPE  AND  POOR 
  PROGNOSTIC  FACTORS 
 
 
 CD3 was more commonly seen in male patients which was statistically 
significant (p=0.021)  
 Statistically significant association could be made out between CD117 
expression and low blast % 
 
 
 
ANTIGEN AGE MALE WBC count 
>50000/mm3 
PLATELET 
COUNT<30000/mm3 
BLAST% >70% 
n % n % N % n % n % 
CD3 0/7 0% 5/7 71.4% 2/7 28.6% 4/7 57% 4/7 57% 
CD7 0/4 0% 1/4 25% 2/4 50% 2/4 50% 2/4 50% 
CD10 1/4 25% 2/4 50% ¼ 25% 2/4 50% 2/4 50% 
CD13 2/23 8.7% 17/23 73.9% 17/23 73.9% 8/23 34.7% 13/23 56.5% 
CD14 0/6 0% 3/6 50% 3/6 50% 3/6 50% 4/6 66.7% 
CD15 0/7 0% 4/7 57.1% 2/7 28.6% 3/7 42.9% 5/7 71.4% 
CD19 0/7 0% 2/7 28.6% 1/7 14.3% 5/7 71.4% 5/7 71.4% 
CD33 2/24 8.3% 15/24 62.5% 6/24 25% 13/24 54.2% 10/24 41.7% 
 CD 34 1/24 4.2% 15/24 62.5% 6/24 25% 12/24 50% 12/24 50% 
CD117 2/16 12.5% 10/16 62.5% 1/16 6.3% 5/16 31.3% 5/16 31.3% 
 P VALUE =0.021 
n = no of positive cases/no of negative cases 
% = positive percentage 
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CD3 + CASES AND MALE GENDER 
 
 
 
 CD3 was more commonly seen in male patients which was statistically  
significant (p=0.021) 
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CD MARKERS AND CASES WITH WBC COUNT >50000/mm
3 
 
 
CD 7 had 50 % of the cases with WBC count more than 50000/mm
3
 but it was not 
statistically significant. 
 
 
 
 
 
0 % 10 % 20% 30% 40% 50%    60%  70%           80% 
CD3 
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 CD 34 
CD117 
 
CASES WITH WBC COUNT >50000/mm
3
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CD MARKERS AND CASES WITH PLATELET COUNT >30000/mm
3 
 
 
CD 3 and CD19 were the most common antigens expressed incases with platelet 
count less than 30000 but was not statistically significant. 
 
0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 70.00% 80.00%
CD3 
CD7 
CD10 
CD13 
CD14 
CD15 
CD19 
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CD 34 
CD117 
CASES WITH PLATELET COUNT <30000/mm
3
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Association of poor prognostic factors with aberrant  
phenotype in AML 
 
 
Poor prognostic factors Ly+AML 
 
Ly-AML 
 
n % n % 
Age 
>(60 yrs) 
2/14 7.1% 1/21 9.5% 
Gender  
(Male) 
6/14 42.9% 17/21 81% 
Wbc count 
> (50,000/mm3) 
3/14 21.4% 6/21 28.6% 
Platelet count  
< (30,000/mm3) 
6/14 42.9% 9/21 42.9% 
Blast % 
>(70%) 
5/14 27.8% 13/21 72.2% 
Ly + AML=lymphoid antigen positive AML,Ly-AML=Lymphoid antigen negative AML   
n = no of positive cases/no of negative cases 
% = positive percentage 
There were no statistically significant association between the Ly+ AML and poor 
prognostic factors. 
 
90 
 
 
 
PROGNOSTIC FACTORS ( MEAN VALUE) 
PROGNOSTIC FACTORS MEAN VALUE OF ALL CASES 
AGE(yrs) 40.65  
WBC COUNT(/mm3) 53979 
PLATELET COUNT(/mm3) 80114 
BLAST % 62.65 
 
PROGNOSTIC FACTORS MEAN VALUE 
CD3 CD7 CD10 CD19 
AGE (yrs ) 35.8 39 43 35.5 
WBC COUNT(mm3) 72328  54960 56975 45857 
PLATELET COUNT(mm3) 111142 61800 59250 69428 
BLAST % 62.5 59.6 69.5 60.4 
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CD MARKERS AND BLAST % MORE THAN 70% 
 
 
 
 
 
CD19 was the most common aberrant antigen having the blast% more than 70%. 
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POOR PROGNOSTIC FACTORS AND ASYNCHRONOUS ANTIGEN 
EXPRESSION 
Poor prognostic 
factors 
CD34+ CD15+ CD34+ CD14+ 
n % N % 
Age 
>(60 yrs) 
0/7 0% 0/4 0% 
Gender  
(Male) 
4/7 5% ¼ 25% 
WBC count 
> (50,000/mm3) 
3/7 42% ¼ 25% 
Platelet count  
< (30,000/mm3) 
4/7 57% 2/4 50% 
Blast % 
>(70%) 
5/7 71% ¼ 25% 
 
 
There were no statistically significant association between asynchronous antigen 
expression and aberrant phenotypes. 
 
 
 
 
 
 
n = no of positive cases/no of negative cases 
% = positive percentage 
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DISCUSSION 
INCIDENCE OF ABERRANT PHENOTYPE 
 Of the 35 samples of newly diagnosed acute myeloid leukemia studied , 17 
cases were of aberrant phenotype in our study. About 49 % of them had 
aberrant phenotype.  
 The incidence of aberrant phenotype varied between different studies. 
Incidence rate ranging from 20 % to as high as 88 % have been reported in 
various studies.  
 In a  recent Study in Saudi Arabia in 40 AML patients aberrant antigens 
were present in 67.5%.
66
 As high as 88% was reported by Bahia et al,2001.
70
 
Most of the  recent studies have reported aberrant phenotype between 50% - 
60% of cases , like Nahla AB Abdulateef et al,2014., Jahedi et al ,2014.
64,69
 
 Low incidence around 20 % were reported only in few studies. Launder et 
al,1996. reported  22% of aberrant phenotypes. Jha R et al, 2013. Have 
reported 35% in their study.
65
 
TYPE OF ABERRANT PHENOTYPE 
 5 cases had lymphoid associated antigen expression alone  which is 14 % of 
cases. 3 cases had asynchronous antigen expression alone which is 8%  of 
cases.  9 cases had both asynchronous antigen expression and lymphoid 
associated antigen expression which is 27 % of cases .  
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 In total lymphoid associated antigen expression is seen in 41 % of cases and 
asynchronous antigen expression in 35 % of cases. 
 In our study lymphoid associated antigen expression was more slightly more 
common than asynchronous antigen expression. But in majority of the 
studies asynchronous antigen expression was the most common like 82 % in 
a study done by Bahia et al,2001.
70
 
 
POSTIVE RATE OF INDIVIDUAL ANTIGEN IN ABERRANT 
PHENOTYPIC AML 
 CD3 , CD19( lymphoid associated antigen ) CD34+ CD15+ (asynchronous 
aberrant phenotype ) were the most common equally expressed aberrant 
phenotypes, each 7  cases. 
 CD 3 and CD 19 are the most common lymphoid associated antigen 
expressed. Each of them were expressed in 20 % of AML cases. About 7 
cases out of 14 cases of  Ly + AML  expressed CD3 which is 50 %.Similarly 
CD19 was also expressed in 50% of the cases Ly + AML .  
 CD 7 was seen in 4 cases , 28.6% of  Ly + AML  aberrant phenotypic cases. 
In most studies CD7 was the most common lymphoid associated antigen 
expressed , like Bahia et al, Jha R et al, 2013.,Zheng et al, 2008., Chang et 
al, 2007.
57,63,70,65
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 Like our study few studies have shown CD19 as the most common lymphoid 
associated antigen expressed. In a study done by Bhushan, Bharat et al, 
2010, the revealed 32 % CD19 expression which the most common aberrant 
antigen and it was expressed more commonly that CD7 (15%).
74
 In a study 
done by  Jha R et al, 2013 CD19 expression was 8% lower compared to 20% 
in CD7 .  
 CD34+ CD15+ was seen in 20 % cases AML cases. Incidence of CD34+ 
CD15+ was low when compared to the previous studies which have reported 
61.5% of CD34+ CD15+ AML cases ( Bahia et al , 2001).  
 In majority of studies expression of early stem cell antigens, CD34 and 
CD117 with mature myeloid antigens was the most common aberrant 
change , like in study by haase et al, macedo et al,wells et al.
75-77
 
  CD117+ CD34+ CD14+ was  in 4 cases about  11.4% . 
Aberrant phenotypes and its association with known adverse prognostic 
factors.  
 Association of adverse prognostic factors and asynchronous antigen 
expression was studied. 
 Adverse prognostic factors which were compared between Ly+ AML and 
Ly- AML groups.  
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 The adverse prognostic factors studied were  Age (>60 yrs ),Gender(male), 
WBC count (>50,000/mm3), Platelet count(<30,000/mm3),  peripheral blast 
% (>70) 
 In the total study population average age was 40.65 years, average WBC 
count  was about 53979/mm
3
, average platelet count was  about  80114/mm
3
 
and average blast % was 62.65%.  
Ly + AML and its association with known adverse prognostic factors.  
 CD3 + Ly+ AML 
 20 % of the AML cases were CD3 +. 
 In CD3 + cases average age was 35.8 years , average WBC count about 
72328 / mm
3
, average platelet count was about 111142 /mm
3
 and average 
blast % was 62.5%. There was no significant difference between the 
CD3+Ly+ AML and Ly – AML in average WBC count platelet count and 
blast %.  
 In CD3 + Ly+ AML males were (5/7)71.4%  , WBC count (>50,000/mm3) 
were (2/7)28.6%, Platelet count(<30,000/mm3) were  (4/7)57%,  peripheral 
blast % (>70) were  (4/7)57%. CD3 was more commonly seen in male  
patients which was statistically significant (p=0.021) 
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CD7 + Ly+ AML 
 In CD7 + cases average age was 39 years , average WBC count about 
54960/mm
3
, average platelet count was about 61800 /mm
3
 and average blast 
% was59.6% .There were no significant between between CD7+Ly+AML 
and Ly- AML in terms of average age , WBC count , platelet count and blast 
%. 
  In CD7+Ly+AML males were (1/4)25%, WBC count (>50,000/mm3) were 
(2/4)50%, Platelet count (<30,000/mm3) were (2/4)50%,  peripheral blast % 
(>70) were (2/4)50%. There were no significant association between 
CD7+Ly+AML and Ly- AML. 
 In few studies CD7+ AML was assoiciated with poor prognosis like lower 
response rate than CD7- AML patients( Hurwitz et al)
78
 
CD10 + Ly+ AML 
 In CD10+ cases average age was 43 years , average WBC count about 
56975/mm
3
, average platelet count  was  about 59250 /mm
3
 and average 
blast % was 69.5% . There were no significant between between 
CD10+Ly+AML and Ly- AML in terms of average age , WBC count , 
platelet count and blast %. 
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 In CD10 + Ly+ AML males were (2/4)50% , WBC count (>50,000/mm3) 
were (1/4)25%, Platelet count (<30,000/mm3) were (2/4)50%, peripheral 
blast % (>70) were (2/4)50%. There were no significant association between 
CD10+Ly+AML and Ly- AML.     
CD19 + Ly+ AML 
 In CD19 + cases average age was 35.5 years , average WBC count about 
45857/mm
3
, average platelet count was  about 69428 /mm
3
 and average blast 
% was 60.4% .  
 In CD19 + Ly+ AML males were (2/7)28.6% , WBC count (>50,000/mm3) 
were (1/7)14.3% , Platelet count (<30,000/mm3) were (5/7)71.4%, 
peripheral blast % (>70) were (5/7)71.4% . Even though there is no 
statistically significant association with adverse prognostic factors , the 
percentage of cases with blast % more than 70% was about 71.4 % which is 
high.(p=0.176). The chi-square statistic for platelet count < 30000/mm
3
 was 
2.917. The P-Value is 0.08. 
BOTH B AND T CELL Ly + AML  
 CD3+,CD19+  was seen in 3/14 cases 21.4%.CD7+,CD19+ was seen in 2/14 
cases 14.3%. Both T cell and B cell Ly + AML was less compared with  T 
cell  marker alone or B cell marker alone  expression. 
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ASYNCHRONOUS ANTIGEN EXPRESSION AND ITS ASSOCIATION 
WITH POOR PROGNOSTIC FACTORS 
 In CD34+CD15+ patients 57% were males, 42 % had WBC count > 
50000/mm
3
,57% had platelet count less than 30000/mm
3
and 71 %  of them 
had blast % more than 70%. 
  CD34+CD1+ patients 25% were males, 25 % had WBC count > 
50000/mm
3
,50% had platelet count less than 30000/mm
3
and 25 %  of them 
had blast % more than 70%. 
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LIMITATIONS OF STUDY 
 One limitation of this study is low number of patients less than 60 yrs of age  
  The results should be confirmed in large group of patients. 
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CONCLUSION 
There is a  frequent occurrence of aberrant phenotype in acute myeloid leukemia in 
India like in other majority of  studies  . CD19  and CD3 were the most commonly 
expressed lymphoid associated antigen. Lymphoid associated expression were 
slightly more common than asynchronous antigen expression. Most common 
asynchronous aberrant phenotype was CD34+CD15+. Aberrant phenotypic 
expression were not associated with poor risk factors in acute myeloid leukemia 
except for common expression of CD3 in males. 
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22 ARULRAJ 82913 33 M 67200 100000 40 -ve +ve -ve -ve -ve -ve -ve +ve +ve -ve Ly+ 
23 SRINIVASAN 60769 32 M 7000 106000 40 +ve -ve -ve +ve -ve -ve -ve -ve -ve +ve Ly+ 
24 KANNAN 59465 66 M 274800 63000 90 -ve -ve -ve +ve -ve -ve -ve +ve -ve -ve Ly - 
25 SHAMEEM 67775 56 M 24000 134000 80 -ve -ve -ve -ve -ve -ve -ve -ve -ve +ve Ly - 
26 NAGABOOSHANAM 45467 50 F 28200 24000 70 +ve -ve -ve -ve -ve -ve +ve -ve +ve -ve Ly+ 
27 LATHA 98302 22 F 22100 315000 60 -ve -ve -ve +ve -ve -ve +ve -ve +ve +ve Ly+ 
28 KANNIYAPPAN 50841 80 M 27200 136000 70 -ve +ve +ve -ve -ve -ve -ve -ve -ve +ve Ly+ 
29 POWNAMMAL 83245 55 F 29300 486000 30 +ve -ve -ve +ve -ve -ve -ve +ve -ve +ve Ly+ 
30 MANIMARAN 77494 35 M 235600 45000 90 -ve -ve -ve +ve +ve -ve -ve -ve -ve -ve Ly - 
31 MUNIYAPPAN 50616 45 M 40000 20000 45 -ve -ve -ve +ve -ve -ve +ve +ve +ve +ve Ly+ 
32 RADHI DEVI 70989 40 F 30000 26000 40 +ve -ve -ve -ve -ve -ve +ve +ve +ve +ve Ly+ 
33 SUBRAMANIAM 82334 55 M 18000 15000 55 -ve -ve -ve +ve -ve -ve -ve +ve -ve -ve Ly - 
34 SHYAMALA 54878 43 M 24000 18000 55 -ve -ve -ve +ve -ve -ve -ve -ve -ve -ve Ly - 
35 DHANALAKSHMI 69043 40 F 10000 25000 40 -ve +ve -ve +ve -ve -ve -ve +ve -ve -ve Ly+ 
 
 
 
 
 
  
 
 
